ATE248596T1 - Verwendung von nicergoline zur behandlung der spastizität - Google Patents
Verwendung von nicergoline zur behandlung der spastizitätInfo
- Publication number
- ATE248596T1 ATE248596T1 AT99956108T AT99956108T ATE248596T1 AT E248596 T1 ATE248596 T1 AT E248596T1 AT 99956108 T AT99956108 T AT 99956108T AT 99956108 T AT99956108 T AT 99956108T AT E248596 T1 ATE248596 T1 AT E248596T1
- Authority
- AT
- Austria
- Prior art keywords
- nicergoline
- treat spasticity
- spasticity
- treat
- pathology
- Prior art date
Links
- 208000008238 Muscle Spasticity Diseases 0.000 title abstract 2
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 title abstract 2
- 229960003642 nicergoline Drugs 0.000 title abstract 2
- 208000018198 spasticity Diseases 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Soil Working Implements (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9814794A FR2786101B1 (fr) | 1998-11-24 | 1998-11-24 | Utilisation de la nicergoline dans le traitement de la spasticite |
| PCT/FR1999/002866 WO2000030642A1 (fr) | 1998-11-24 | 1999-11-22 | Utilisation de la nicergoline dans le traitement de la spasticite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE248596T1 true ATE248596T1 (de) | 2003-09-15 |
Family
ID=9533131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99956108T ATE248596T1 (de) | 1998-11-24 | 1999-11-22 | Verwendung von nicergoline zur behandlung der spastizität |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6380208B2 (de) |
| EP (1) | EP1133295B1 (de) |
| JP (1) | JP4936594B2 (de) |
| AT (1) | ATE248596T1 (de) |
| AU (1) | AU1278500A (de) |
| DE (1) | DE69911052T2 (de) |
| DK (1) | DK1133295T3 (de) |
| ES (1) | ES2201801T3 (de) |
| FR (1) | FR2786101B1 (de) |
| PT (1) | PT1133295E (de) |
| WO (1) | WO2000030642A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2786101B1 (fr) * | 1998-11-24 | 2002-07-05 | Aventis Laboratoire | Utilisation de la nicergoline dans le traitement de la spasticite |
| FR2786100B1 (fr) * | 1998-11-24 | 2002-03-01 | Aventis Laboratoire | Nouvelle application therapeutique de la nicergoline |
| FR2801793B1 (fr) * | 1999-12-01 | 2003-07-04 | Aventis Pharma Sa | Association d'une ergoline et de riluzole et son utilisation comme medicament |
| US6297254B1 (en) | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
| DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3228943A (en) | 1962-06-11 | 1966-01-11 | Lumilysergol derivatives | |
| YU39278B (en) * | 1976-12-22 | 1984-10-31 | Lek Tovarna Farmacevtskih | Process for preparing 5-bromo nicotinic acid esters |
| FR2492258A1 (fr) | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| IT1252163B (it) * | 1991-12-03 | 1995-06-05 | Poli Ind Chimica Spa | Composizioni farmaceutiche per la neuroprotezione nelle malattie neurologiche di carattere degenerativo o su base ischemica |
| JP2864885B2 (ja) * | 1992-07-02 | 1999-03-08 | 田辺製薬株式会社 | ニセルゴリン含有経口投与製剤 |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| IT1256743B (it) * | 1992-12-18 | 1995-12-15 | Giorgio Pifferi | Composizioni farmaceutiche a rilascio controllato contenenti nicergolina |
| US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US6294517B1 (en) * | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| JP2001520999A (ja) * | 1997-10-28 | 2001-11-06 | アシビ， エルエルシー | 女性の性的機能不全の処置 |
| FR2777781B1 (fr) * | 1998-04-24 | 2004-04-09 | Rhone Poulenc Rorer Sa | Associations riluzole et l-dopa pour le traitement de la maladie de parkinson |
| DE19842416A1 (de) * | 1998-09-16 | 2000-04-13 | Max Planck Gesellschaft | Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden |
| FR2785808B1 (fr) * | 1998-11-13 | 2002-12-06 | Aventis Laboratoire | Association riluzole et alpha-tocopherol |
| FR2786099B1 (fr) * | 1998-11-24 | 2000-12-29 | Aventis Laboratoire | Nouvelle application therapeutique de la 1,6-dimethyl-8beta- hydroxymethyl-10alpha-methoxyergoline |
| FR2786101B1 (fr) * | 1998-11-24 | 2002-07-05 | Aventis Laboratoire | Utilisation de la nicergoline dans le traitement de la spasticite |
| FR2786100B1 (fr) * | 1998-11-24 | 2002-03-01 | Aventis Laboratoire | Nouvelle application therapeutique de la nicergoline |
| US6297254B1 (en) * | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
-
1998
- 1998-11-24 FR FR9814794A patent/FR2786101B1/fr not_active Expired - Fee Related
-
1999
- 1999-11-22 AU AU12785/00A patent/AU1278500A/en not_active Abandoned
- 1999-11-22 ES ES99956108T patent/ES2201801T3/es not_active Expired - Lifetime
- 1999-11-22 PT PT99956108T patent/PT1133295E/pt unknown
- 1999-11-22 JP JP2000583525A patent/JP4936594B2/ja not_active Expired - Fee Related
- 1999-11-22 DK DK99956108T patent/DK1133295T3/da active
- 1999-11-22 EP EP99956108A patent/EP1133295B1/de not_active Expired - Lifetime
- 1999-11-22 WO PCT/FR1999/002866 patent/WO2000030642A1/fr not_active Ceased
- 1999-11-22 AT AT99956108T patent/ATE248596T1/de active
- 1999-11-22 DE DE69911052T patent/DE69911052T2/de not_active Expired - Lifetime
-
2001
- 2001-05-23 US US09/863,787 patent/US6380208B2/en not_active Expired - Lifetime
-
2002
- 2002-01-29 US US10/059,869 patent/US6713493B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1133295A1 (de) | 2001-09-19 |
| JP4936594B2 (ja) | 2012-05-23 |
| DK1133295T3 (da) | 2003-12-22 |
| PT1133295E (pt) | 2004-01-30 |
| US6713493B2 (en) | 2004-03-30 |
| FR2786101A1 (fr) | 2000-05-26 |
| ES2201801T3 (es) | 2004-03-16 |
| WO2000030642A1 (fr) | 2000-06-02 |
| EP1133295B1 (de) | 2003-09-03 |
| DE69911052T2 (de) | 2004-08-19 |
| DE69911052D1 (de) | 2003-10-09 |
| JP2003530298A (ja) | 2003-10-14 |
| FR2786101B1 (fr) | 2002-07-05 |
| AU1278500A (en) | 2000-06-13 |
| US6380208B2 (en) | 2002-04-30 |
| US20020013332A1 (en) | 2002-01-31 |
| US20020086875A1 (en) | 2002-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE324908T1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| DE69724016D1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege | |
| DE69936335D1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| ATE286895T1 (de) | Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten | |
| DE69727695D1 (de) | Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE60130365D1 (de) | Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen. | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE248596T1 (de) | Verwendung von nicergoline zur behandlung der spastizität | |
| BR9808923B1 (pt) | processos para fazer compostos inibidores de ciclooxigenase-2, e, compostos intermediÁrios para fazer inibidores de ciclooxigenase-2. | |
| DE69611598D1 (de) | Azoderivate von 5-aminosalicylsäure zur behandlung von enzündlichen darmerkrankungen | |
| DE69931487D1 (de) | Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation | |
| DE60021252D1 (de) | Antikonvulsiva zur behandlung von autismus | |
| DE59704933D1 (de) | Verwendung von PHMB zur Behandlung von Tumorerkrankungen | |
| DE60041365D1 (de) | Verwendung von Riluzol zur Behandlung Multipler Sklerose | |
| ATE306280T1 (de) | Verwendung von il6r- il6 chimären für die behandlung von neurodegenerativen erkankungen | |
| DE69736180D1 (de) | Behandlung von manischen erkrankungen | |
| DE69910425D1 (de) | Neue therapeutische verwendung von nicergoline | |
| ATE251167T1 (de) | Oxazinocarbazole zur behandlung von cns- erkrankungen | |
| BR9709264A (pt) | Processo para produzir e composto | |
| DE60124093D1 (de) | S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen. | |
| DE69924385D1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| ATE217524T1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1133295 Country of ref document: EP |